Difference between revisions of "CNS lymphoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 3: Line 3:
 
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
 
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
  
{{TOC limit|limit==3}}
+
{{TOC limit|limit=3}}
  
 
=Untreated=
 
=Untreated=

Revision as of 15:51, 3 September 2013

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.


Untreated

EORTC-BTG Protocol 26952

Regimen

Level of Evidence: Phase II

Induction phase

45 days, those with PR or CR proceed to:

Maintenance phase

6-week cycles x 5 cycles

References

  1. Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B; European Organization for Research and Treatment of Cancer Brain Tumor Group. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003 Jul 15;21(14):2726-31. link to original article contains verified protocol PubMed

MT-R

Regimen, Rubenstein, et al. 2013 (CALGB 50202)

Level of Evidence: Phase II

Induction phase

14-day cycles x 8 cycles

Patients achieving CR or CRu were given one additional cycle of methotrexate & temozolomide, followed by consolidation therapy:

Consolidation

One course

References

  1. Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 Jul 1. [Epub ahead of print] link to original article contains verified protocol PubMed

Relapsed/refractory

High-dose Methotrexate (MTX) & Ifosfamide

Regimen

Level of Evidence: Retrospective

  • Methotrexate (MTX) 4000 mg/m2 IV over 4 hours once on day 1
  • Ifosfamide (Ifex) 1500-2000 mg/m2 IV over 3 hours once daily on days 3 to 5
  • Mesna (Mesnex) for prophylaxis of hemorrhagic cystitis
  • Folinic acid (Leucovorin) rescue starting 24 hours after start of methotrexate infusion
  • Sodium bicarbonate via IV fluid or PO routes used for urine alkalinization to maintain urine pH of at least 8
  • Check methotrexate levels 24, 48, and 72 hours after completion of methotrexate infusion.

Methotrexate (MTX) dose adjusted for creatinine clearances <100 mL/min according to the following formula:

  • Dose of methotrexate = (creatinine clearance/100) x 4000 mg/m2; the paper did not specify what method was used for calculating creatinine clearance. Patients with creatinine clearance <50 mL/min were excluded from the study.

up to 8 cycles (reference did not list timing/criteria to be used for next cycle of therapy)

References

  1. Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol. 2009 Feb;88(2):133-9. Epub 2008 Aug 5. link to original article contains verified protocol PubMed